March 8th 2007
AstraZeneca is introducing new technology to safeguard patients and protect its products from threats such as counterfeiting, tampering and illegal diversion. With the launch of the Serialized Authentication Program for NEXIUM®, AstraZeneca will become one of the first pharmaceutical companies to implement a comprehensive system to serialize and authenticate its pharmaceutical products down to the unit-level. [click link for full article]
March 8th 2007
AstraZeneca is introducing new technology to safeguard patients and protect its products from threats such as counterfeiting, tampering and illegal diversion. With the launch of the Serialized Authentication Program for NEXIUM®, AstraZeneca will become one of the first pharmaceutical companies to implement a comprehensive system to serialize and authenticate its pharmaceutical products down to the unit-level. [click link for full article]
March 3rd 2007
Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceuticals company Actavis Group (ICEX: ACT), today announced that it has received approval from the U.S. Food & Drug Administration (FDA) to market Ranitidine Oral Solution USP. Due to Actavis’s first-to-file status, the FDA has granted Actavis a 180-day marketing exclusivity that will commence with the distribution of the product in the coming weeks. [click link for full article]